Soy Protein Under Fire, But Experts, Industry Confident In Heart Health Claim
This article was originally published in The Tan Sheet
Nutrition experts say a citizen petition requesting FDA revoke a health claim linking soy protein to heart health benefits weakens its own argument by citing data selectively and in error
You may also be interested in...
The European Food Safety Authority concludes that a cause and effect relationship is not established between the consumption of soy protein and lower levels of low-density lipoprotein cholesterol, which lowers the risk of coronary heart disease. Though petitioners submitted 40 studies, the regulatory authority rejected most because they did not test soy protein but soy protein isolate or soy foods containing other substances that have a proven effect on heart health. The petitioners submitted four additional meta-analyses, all of which EFSA said failed to show a relationship between the consumption of soy protein and lower levels of LDL. The soy heart health claim also is under fire in the U.S., where nutrition groups submitted a 2008 citizen petition to FDA to have the health claim overturned and the American Heart Association recommended the claim be revoked (1"The Tan Sheet" Sept. 1, 2008)
The Council for Responsible Nutrition recommends FDA maintain the health claim linking soy protein and reduced heart disease risk and consider adding language to address the "possible contribution" of other soy components
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.